Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Brennan

Neurological Surgery Norfolk, VA Medical Doctor

NPI 1447217666 CMS profile 292522

301 Riverview Ave Ste 202A, Norfolk, VA 23510

Open in the dashboard

General payments

$129,741

130 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Brennan of Norfolk, VA is reported in the CMS Open Payments database as having received $129,741 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,796 17
2024 General $2,985 14
2023 General $13,632 21
2022 General $23,991 27
2021 General $25,430 12
2020 General $26,130 13
2019 General $34,776 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Brennan
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to James Brennan were reported at $2,796. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year James Brennan Neurological Surgery median Middle half National median
2019 $34,776 $582 $138–$3,006 $163
2020 $26,130 $294 $76–$2,174 $114
2021 $25,430 $387 $105–$2,432 $132
2022 $23,991 $542 $139–$2,989 $149
2023 $13,632 $534 $145–$2,697 $160
2024 $2,985 $574 $155–$3,046 $164
2025 $2,796 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Seaspine Orthopedics Corporation $104,033 43 payments
  2. Orthofix Medical, Inc. $17,229 20 payments
  3. Boston Scientific Corporation $7,608 52 payments
  4. Medtronic, Inc. $334 5 payments
  5. Intrinsic Therapeutics $239 1 payment
  6. Cerapedics, Inc. $92 2 payments
  7. SPR Therapeutics, Inc $81 1 payment
  8. Microtransponder, Inc. $32 1 payment
  9. Shire North American Group Inc $23 1 payment
  10. Misonix Inc $22 1 payment
  11. Other $48 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $107,200 26 payments
  2. Consulting Fee $8,625 8 payments
  3. Food and Beverage $5,406 79 payments
  4. Travel and Lodging $5,109 16 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,400 1 payment
Products named General payments · program years 2019–2025
  1. Sierra Spine Hardware Systems $30,538 11 payments
  2. Sierra Spine Hardware Systems $26,803 4 payments
  3. Sierra OCT Spine Hardware Systems $25,416 4 payments
  4. Sierra OCT Spine Hardware Systems $24,425 4 payments
  5. Mariner $4,826 4 payments
  6. Manta Ray $4,750 2 payments
  7. SPECTRA WAVEWRITER $4,625 13 payments
  8. Strand $3,250 1 payment
  9. Skipjack $2,228 5 payments
  10. 7D Surgical System $2,080 5 payments
  11. Other $9,656 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

83

Median for Neurosurgery: 83

Drug cost

$1,092

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Baclofen Generic 14 $308
Methocarbamol Generic 15 $306
Tizanidine Hcl Generic 25 $222
Nabumetone Generic 13 $212
Meloxicam Generic 16 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$193,922

Medicare's payments for the services billed

Medicare patients

517

Average age 77

Services billed

1,316

277 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Ischemic heart disease 38%
Heart failure 32%
Depression 32%
Chronic kidney disease 31%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record